Clinical Trials
28 trialsNCT04971525 2025-07-08
A Study to Check How Often People Treated With Darvadstrocel for Crohn's Disease Are Diagnosed With Cancer
Takeda
Withdrawn
NCT05796245 2025-06-04
A Study to Learn About the Study Medicine Called Infliximab (Genetical Recombination)[Infliximab Biosimilar 3] in People With Rheumatoid Arthritis, Ulcerative Colitis, Crohn's Disease, or Psoriasis
Pfizer
Completed
NCT04655807 2025-04-27
DUET
Janssen Research & Development, LLC
Phase 2 Withdrawn
NCT01804166 2025-02-04
A Research Study to Bank Samples for Future Evaluation to Identify Biomarkers That Predispose Crohn's Disease and Ulcerative Colitis Patients to Develop Hepatosplenic T-Cell Lymphoma (HSTCL)
Janssen Scientific Affairs, LLC
Phase 4 Completed
NCT06710067 2024-12-13
Urine Metabolites in the Diagnosis of Disease
Luventix, Inc.
Recruiting
NCT06583395 2024-11-01
QUANTUM
VitaMed Research LLC
Enrolling by invitation
NCT03710486 2024-05-30
EVOLVE-IBERIA
Takeda
Completed
NCT05635266 2024-05-07
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Sanguine Biosciences
Unknown
NCT01931644 2024-04-18
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
Sanguine Biosciences
Completed
NCT05579444 2023-12-15
Systems Biology of Gastrointestinal and Related Diseases
Viome
Terminated
NCT01714726 2021-05-26
Evaluation of Efficacy and Safety of MEDI2070 in Patients With Active, Moderate-to-severe Crohn's Disease.
AstraZeneca
Phase 2 Completed
NCT02574637 2021-05-26
Evaluation of Efficacy and Safety of Brazikumab (MEDI2070) in Participants With Active, Moderate to Severe Crohn's Disease
AstraZeneca
Phase 2 Terminated
NCT03452501 2021-02-23
Safety and Effectiveness Study of Remsima® in the Treatment of Inflammatory Bowel Diseases Among Saudi Arabia Patients
Hikma Pharmaceuticals LLC
Completed
NCT02499783 2019-01-04
Study to Evaluate the Safety and Efficacy of Adalimumab in Chinese Subjects With Moderate to Severe Crohn's Disease
AbbVie
Phase 3 Completed
NCT01560377 2018-12-11
PILLAR II
Novadaq Technologies ULC, now a part of Stryker
Phase 1 Completed
NCT00552058 2018-08-09
Study to Evaluate Efficacy and Safety of Certolizumab Pegol for Induction of Remission in Patients With Crohn's Disease
UCB Pharma
Phase 3 Completed
NCT00333788 2018-08-07
Welcome2
UCB Pharma
Phase 3 Completed
NCT03090139 2018-06-26
Sub-optimal Response to Anti-Tumor Necrosis Factor's in Inflammatory Bowel Disease in Emerging Markets
Takeda
Completed
NCT03019016 2017-10-26
Comparison of Intracorporeal and Extracorporeal Anastomoses for Minimally Invasive Right Colectomy
Intuitive Surgical
Completed
NCT01860846 2017-06-16
IDEA
AbbVie
Completed
NCT01369329 2016-12-07
A Study to Evaluate the Safety and Efficacy of Ustekinumab in Patients With Moderately to Severely Active Crohn's Disease Who Have Failed or Are Intolerant to Tumor Necrosis Factor (TNF) Antagonist Therapy (UNITI-1)
Janssen Research & Development, LLC
Phase 3 Completed
NCT00584740 2015-03-31
Efficacy, Safety and Tolerability of AIN457 in Moderate to Severe Active Crohn's Disease
Novartis
Phase 2 Terminated
NCT00440817 2014-04-10
An Observational Study of Lymphoma in Patients With Rheumatoid Arthritis or Crohn's Disease.
Centocor Ortho Biotech Services, L.L.C.
Completed
NCT01880918 2013-06-19
A RETROspective Data Collection of comPRESSion Anastomosis Using the ColonRing
novoGI
Unknown
NCT01301417 2013-06-05
RETROPRESS
novoGI
Completed
NCT00354367 2012-05-28
Evaluate Efficacy of Certolizumab in Crohn's Patients With Draining Fistulas
UCB Pharma
Phase 3 Withdrawn
NCT00358683 2012-05-28
A Trial Evaluating Safety of Chronic Therapy With Certolizumab Pegol in Crohn's Disease
UCB Pharma
Phase 3 Withdrawn
NCT00297648 2011-08-31
MUSIC
UCB Pharma
Phase 3 Completed